Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)

Leukemia Research

Volumn 37, Issue 7, 2013, Pages 809-815

  Scavullo, Cinzia ^a   Servida, Federica ^a   Lecis, Daniele ^b   Onida, Francesco ^a   Drago, Carmelo ^c   Ferrante, Luca ^c   Seneci, Pierfausto ^a,c   Barcellini, Wilma ^a   Lionetti, Marta ^a   Todoerti, Katia ^a   Neri, Antonino ^a   Delia, Domenico ^b   Deliliers, Giorgio Lambertenghi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Centro Interdisciplinare Studi Biomolecolari e Applicazioni Industrials (CISI)   (Italy)

Author keywords

Apoptosis; B CLL; Caspases; Smac mimetics; Therapy; TNF

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 2; INHIBITOR OF APOPTOSIS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMAC 66; SMAC34; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; BINDING AFFINITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LEUKEMIA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGOPEPTIDES; PEPTIDOMIMETICS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878499550     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.03.016     Document Type: Article

References (35)

1. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
2. Shanafelt T.D., Ghia P., Lanasa M.C., Landgren O., Rawstron A.C. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 2010, 24:512-520.
3. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
4. Huerta S., Goulet E.J., Huerta-Yepez S., Livingston E.H. Screening and detection of apoptosis. J Surg Res 2007, 139:143-156.
5. Fuentes-Prior P., Salvesen G.S. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 2004, 384:201-232.
6. Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev 1999, 13:239-252.
7. Silva K.L., Vasconcellos D.V., Castro E.D., Coelho A.M., Linden R., Maia R.C. Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 2006, 11:277-285.
8. Chen R., Plunkett W. Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010, 23:155-166.
9. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000, 6:1796-1803.
10. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3:401-410.
11. Liu Z., Sun C., Olejniczak E.T., Meadows R.P., Betz S.F., Oost T., et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000, 408:1004-1008.
12. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
13. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
14. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703.
15. Petersen S.L., Wang L., Yalcin-Chin A., Li L., Peyton M., Minna J., et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007, 12:445-456.
16. Lu J., Bai L., Sun H., Nikolovska-Coleska Z., McEachern D., Qiu S., et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008, 68:9384-9393.
17. Probst B.L., Liu L., Ramesh V., Li L., Sun H., Minna J.D., et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 2010, 17:1645-1654.
18. Chen D.J., Huerta S. Smac mimetics as new cancer therapeutics. Anticancer Drugs 2009, 20:646-658.
19. Liu F.T., Agrawal S.G., Gribben J.G., Ye H., Du M.Q., Newland A.C., et al. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 2008, 111:2797-2805.
20. Ruiz S., Krupnik Y., Keating M., Chandra J., Palladino M., McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006, 5:1836-1843.
21. Kabore A.F., Sun J., Hu X., McCrea K., Johnston J.B., Gibson S.B. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006, 11:1175-1193.
22. Seneci P., Bianchi A., Battaglia C., Belvisi L., Bolognesi M., Caprini A., et al. Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy. Bioorg Med Chem 2009, 17:5834-5856.
23. Nikolovska-Coleska Z., Wang R., Fang X., Pan H., Tomita Y., Li P., et al. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem 2004, 332:261-273.
24. Cossu F., Malvezzi F., Canevari G., Mastrangelo E., Lecis D., Delia D., et al. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1. Protein Sci 2010, 19:2418-2429.
25. Mattioli M., Agnelli L., Fabris S., Baldini L., Morabito F., Bicciato S., et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005, 24:2461-2473.
26. Schadt E.E., Li C., Ellis B., Wong W.H. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl 2001, (Suppl. 37):120-125.
27. Kern D.H., Morgan C.R., Hildebrand-Zanki S.U. In vitro pharmacodynamics of 1-beta-d-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res 1988, 48:117-121.
28. Lecis D., Drago C., Manzoni L., Seneci P., Scolastico C., Mastrangelo E., et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and bortezomib. Br J Cancer 2010, 102:1707-1716.
29. Servida F., Lecis D., Scavullo C., Drago C., Seneci P., Carlo-Stella C., et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest New Drugs 2011, 29:1264-1275.
30. Frenzel L.P., Patz M., Pallasch C.P., Brinker R., Claasen J., Schulz A., et al. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol 2011, 152:191-200.
31. Loeder S., Zenz T., Schnaiter A., Mertens D., Winkler D., Dohner H., et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009, 69:8977-8986.
32. Grzybowska-Izydorczyk O., Cebula B., Robak T., Smolewski P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 2010, 46:800-810.
33. Wu H., Tschopp J., Lin S.C. Smac mimetics and TNFalpha: a dangerous liaison?. Cell 2007, 131:655-658.
34. Laukens B., Jennewein C., Schenk B., Vanlangenakker N., Schier A., Cristofanon S., et al. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 2011, 13:971-979.
35. Darding M., Feltham R., Tenev T., Bianchi K., Benetatos C., Silke J., et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ 2011, 18:1376-1386.